Answers are grounded in this paper and cite their sources.
This report investigates the CD4-gp120 interaction's role in AIDS, suggesting a potential therapeutic target.
Infection by the human immunodeficiency virus (HIV) leads to progressive destruction of the CD4+ subset of T lymphocytes, resulting in immunodeficiency and AIDS. The selectivity of CD4+ cell destruction is due to the specific binding of gp120, the external envelope glycoprotein of HIV, to CD4, initiating viral entry. Binding of gp120 to CD4 on the cell surface may also lead to CD4+ cell depletion by inappropriate immune targeting, and may interfere with CD4+ cell function and ontogeny by disrupting CD4-mediated cell signaling. The CD4-gp120 interaction is thus an obvious target for AIDS therapeutics.
No takes yet. Share an insight, caveat, or question.
Capon et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: